Optimized Stent Performance
COBRA PzF NanoCoated Coronary Stent (NCS)
Designed with
Healing in mind
The revolutionary COBRA PzF NCS is a new nanocoated, non drug-eluting stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT requirement.1
Designed with Healing in Mind
The revolutionary COBRA PzF NCS is a new nanocoated, non drug-eluting stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT requirement.1
Exceptional Safety & Efficacy
In the FDA PzF SHIELD IDE trial, COBRA PzF NCS demonstrated an excellent safety profile with minimum 1-month DAPT.1,2
Several additional studies demonstrated low rates of stent thrombosis, zero late stent thrombosis with low DAPT.
At 270 Days
0%
Stent Thrombosis2
4.6%
TLR‡2
1
Month DAPT1
minimum requirement
COBRA PzF NCS indications include patients with diabetes mellitus
Polyzene-F NanoCoating
Makes the Difference
Polyzene-F is a nano-thin surface coating that has been studied extensively in the past 20+ years, demonstrating thrombo-resistant, anti-inflammatory and rapid healing effects in preclinical studies.3-7*
Polyzene-F NanoCoating Makes the Difference
Polyzene-F is a nano-thin surface coating that has been studied extensively in the past 20+ years, demonstrating thrombo-resistant, anti-inflammatory and rapid healing effects in preclinical studies.3-7*
Delivery System Specifications
Product Ordering Information
COBRA PzF NCS is approved and commercially available for purchase in the U.S. Contact a CeloNova Sales Representative today for more information.
* AS DEMONSTRATED IN HUMAN AND PRECLINICAL STUDIES.
Correlation between bench testing, animal studies and humans have not been determined.
‡ Stent thrombosis defined as ARC Definite, Probable and Possible; stent thrombosis and cTLR assessed at 270 days [95% Confidence Interval ST, 0.00%, 1.29%, cTLR, 2.45%, 7.67%]
+ For more information about the COBRA REDUCE IDE trial, please visit: clinicaltrials.gov/ct2/show/NCT02594501.
Correlation between bench testing, animal studies and humans have not been determined.
‡ Stent thrombosis defined as ARC Definite, Probable and Possible; stent thrombosis and cTLR assessed at 270 days [95% Confidence Interval ST, 0.00%, 1.29%, cTLR, 2.45%, 7.67%]
+ For more information about the COBRA REDUCE IDE trial, please visit: clinicaltrials.gov/ct2/show/NCT02594501.
- Levine G, Bates E, Bittl J, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Circulation. 2016;134(10):e123-55.
- Cutlip D, Garrat K, Novack V, et al. 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System. JACC Cardiovasc Interv. 2017;10(2):160-167.
- Koppara T, Sakakura K, Pacheco E, et al. Preclinical evaluation of a novel polyphosphazene surface modified stent. International Journal of Cardiology. 2016; 222:217-225.
- Mrowietz C, Franke R, Seyfert U, et al. Haemocompatibility of polymer-coated stainless steel stents as compared to uncoated stents. Clinical Hemorheology and Microcirculation. 2005; 32:89–103.
- Richter G, Stampfl U, Stampfl S, et al. A New Polymer Concept for Coating of Vascular Stents Using PTFEP (poly(bis(trifluoroethoxy)phosphazene) to Reduce Thrombogenicity and Late In-Stent Stenosis. Investigative Radiology. 2005; 40(4):210-218.
- Radeleff B, Thierjung H, Stampfl U, et al. Restenosis of the CYPER-Select, TAXUS-Express, and Polyzene-F NanoCoated Cobalt-Chromium Stents in the Minipig Coronary Artery Model. Cardiovasc Intervent Radiol. 2007.
- Tamburino C, Giacoppo D, Capodanno D, et al. The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial. Interv.Cardiol. 2011; 3 (4): 451-460.